#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Peripheral primitive neuroectodermal tumour of soft tissue Indolent systemic mastocytosis Friedreich's ataxia Spinal cord injury Neoplasm malignant Neoplasm Granulomatosis with polyangiitis Small cell lung cancer recurrent Adenovirus infection Retinopathy proliferative Thalassaemia Hyperinsulinism Oesophageal atresia Follicle centre lymphoma follicular grade I II – III refractory Antithrombin III deficiency More trials…

    Learn about Rare Diseases

    Vascular malformation – Diagnostics Adrenocortical carcinoma – Treatment Chondrosarcoma – Basic Information Isodicentric chromosome 15 syndrome – Basic Information Hairy cell leukaemia Alexander disease – Treatment Sarcoma – Life with Disease Lysosomal storage disorder – Diagnostics Brain stem glioma – Treatment Ewing’s sarcoma metastatic – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mesenchymal Cells Wt1/Il15/Il15Ra Mrna Dc Eo2317 Hdp-101 ZELENECTIDE PEVEDOTIN Carfilzomib Landiolol Hydrochloride Mitoxantrone Desonide Theophylline Aavanc80-3'Hotof Cabergoline Betula Pollen Extract Autogene Cevumeran Ptc518 Methylone REGN7999 Palbociclib [14C]ZIPALERTINIB Lerodalcibep More therapies…

    Learn about Your Condition

    Immune-mediated myositis Hypersensitivity Indolent systemic mastocytosis Sepsis Medullary thyroid cancer Pouchitis Perineal injury Pyelonephritis Primary hypogonadism Hepatitis D Fibrosarcoma metastatic Systemic mastocytosis Bladder cancer recurrent Clostridium difficile colitis External cephalic version More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Sanatorium profesora Arenbergera

Sanatorium profesora Arenbergera

BOLZANOVA 7, Prague, 110 00, Czechia

Want to learn more about this study or check if you can participate? Contact us.

  • Comparison of zasocitinib and deucravacitinib in adults with moderate to severe plaque psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Deucravacitinib
    • Zasocitinib
    Bulgaria Czechia France Latvia Poland

  • Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Apremilast
    • Zasocitinib
    Bulgaria Czechia France Germany Greece Hungary +3

  • Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Envudeucitinib
    Austria Belgium Bulgaria Czechia Estonia France +7

  • Study on the Effectiveness and Safety of Lunsekimig (SAR443765) for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • LUNSEKIMIG
    Czechia Poland

  • Study on Long-term Safety and Effectiveness of Zasocitinib for Patients with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Zasocitinib
    Bulgaria Czechia France Germany Hungary Italy +3

  • Study on the Effectiveness of Dupilumab Injections for Itch Relief in Adults with Lichen Simplex Chronicus

    Not recruiting

    3 1
    Investigated Diseases:
    • Neurodermatitis
    Investigated Drugs:
    • Dupilumab
    Belgium Czechia Germany Greece Hungary Italy +1

  • Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

    Not recruiting

    3 1
    Investigated Diseases:
    • Neurodermatitis
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    Belgium Czechia Germany Poland Spain

  • Study on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Apremilast
    • Envudeucitinib
    Belgium Bulgaria Czechia Germany Poland Portugal

  • Study on the Safety and Effectiveness of APG777 for Patients with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Apg777
    Czechia France Germany Hungary Poland Spain

  • Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Nemolizumab
    Austria Belgium Bulgaria Czechia Estonia France +8
Previous Page
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!